CDK4/6 inhibitor plus hormone therapy for high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old.
- Your breast cancer is hormone-receptor-positive (ER and PR positive) and HER2-positive.
- You had early-stage breast cancer that was removed by mastectomy, and it was high risk (cancer in lymph nodes, or didn't fully respond to chemo before surgery).
- You finished a full year of anti-HER2 therapy (like Herceptin, Kadcyla, or a targeted pill) within the last 12 months.
- Your heart, liver, and kidney function are good, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This trial tests whether a CDK4/6 inhibitor given after surgery can help prevent breast cancer from coming back. It is for people with HR-positive, HER2-negative breast cancer that has not spread to other parts of the body.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial tests a combination of three anti-HER2 drugs plus a CDK4/6 inhibitor before surgery for women with a type of breast cancer that is both HER2-positive and ER-positive. It aims to see if this treatment can shrink tumors more effectively before surgery.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.